Browsing Tag
DMX-200
5 posts
Dimerix (ASX: DXB) secures A$34m funding but lenders get 30% of milestones
Dimerix Limited has secured A$34 million of loan commitments and initially plans to draw only A$17 million, saying existing cash and the facility can fund its ACTION3 Phase 3 and DMX-652 Phase 2 programmes. The structure avoids immediate equity dilution but carries 10% compounded interest and gives lenders a share of future DMX-200 licensing milestones.
Dimerix (ASX: DXB) buys Phase 2-ready DMX-652 in deal worth up to $292m
Dimerix buys Phase 2-ready DMX-652 for US$5 million upfront, widening its kidney pipeline while taking on milestones, royalties and execution risk ahead.
Dimerix (ASX: DXB) acquires Phase 2-ready DMX-652 as acute kidney injury deal reshapes renal pipeline
Dimerix has acquired a Phase 2-ready acute kidney injury candidate with an open United States clinical application, giving the biotechnology company a nearer-term catalyst beyond its long-running ACTION3 programme.
DXB rockets on Japan orphan drug win — can Dimerix finally deliver an FSGS breakthrough?
Dimerix (ASX: DXB) secures orphan drug designation in Japan for DMX-200, strengthening its global Phase 3 kidney trial program. Find out what’s next.
Dimerix stock up 74% YTD as FSGS asset DMX-200 gets safety green light
Dimerix’s FSGS drug candidate DMX-200 clears key Phase 3 safety review with no concerns. Learn how this ASX biotech aims to reshape kidney disease treatment.